{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:20:30Z","timestamp":1791109230203,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2001,7,1]],"date-time":"2001-07-01T00:00:00Z","timestamp":993945600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2001,7,1]],"date-time":"2001-07-01T00:00:00Z","timestamp":993945600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2001,7]]},"DOI":"10.1007\/bf02982552","type":"journal-article","created":{"date-parts":[[2008,11,3]],"date-time":"2008-11-03T17:29:42Z","timestamp":1225733382000},"page":"70-75","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Successful Treatment With a Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8, Rituximab) for a Patient With Relapsed Mantle Cell Lymphoma Who Developed a Human Anti-Chimeric Antibody"],"prefix":"10.1007","volume":"74","author":[{"given":"Takahiro","family":"Maeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuaki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Tawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reishi","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Yakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chizuko","family":"Tsutsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Onimaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeru","family":"Kamihira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Tomonaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2001,7,1]]},"reference":[{"key":"BF02982552_CR1","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/00000478-199207000-00001","volume":"16","author":"PM Banks","year":"1992","unstructured":"Banks PM, Chan J, Cleary ML, et al. Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data.Am J Surg Pathol. 1992;16:637\u2013640.","journal-title":"Am J Surg Pathol."},{"issue":"suppl 2","key":"BF02982552_CR2","first-page":"29","volume":"31","author":"K Lennert","year":"1975","unstructured":"Lennert K, Stein H, Kaiserling E. Cytological and functional criteria for the classification of malignant lymphomata.Br J Cancer. 1975;31(suppl 2):29\u201343.","journal-title":"Br J Cancer."},{"key":"BF02982552_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/1097-0142(19810915)48:6<1415::AID-CNCR2820480625>3.0.CO;2-N","volume":"48","author":"DD Weisenburger","year":"1981","unstructured":"Weisenburger DD, Nathwani BN, Diamond LW,Winberg CD, Rappaport H. Malignant lymphoma, intermediate lymphocytic type: a clinicopathologic study of 42 cases.Cancer. 1981;48:15\u201325.","journal-title":"Cancer"},{"key":"BF02982552_CR4","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/1097-0142(19820401)49:7<1429::AID-CNCR2820490720>3.0.CO;2-5","volume":"49","author":"DD Weisenburger","year":"1982","unstructured":"Weisenburger DD, Kim H, Rappaport H. Mantle-zone lymphoma: a follicular variant of intermediate lymphocytic lymphoma.Cancer. 1982;49:1429\u20131438.","journal-title":"Cancer"},{"key":"BF02982552_CR5","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2","volume":"49","author":"The Non-Hodgkin\u2019s Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of","year":"1982","unstructured":"The Non-Hodgkin\u2019s Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin\u2019s lymphomas: summary and description of a working formulation for clinical usage.Cancer. 1982;49:2112\u20132135.","journal-title":"Cancer"},{"key":"BF02982552_CR6","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1200\/JCO.1998.16.5.1922","volume":"16","author":"W Hiddemann","year":"1998","unstructured":"Hiddemann W, Unterhalt M, Herrmann R, et al. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group.J Clin Oncol. 1998;16:1922\u20131930.","journal-title":"J Clin Oncol."},{"key":"BF02982552_CR7","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1038\/sj.leu.2401121","volume":"12","author":"H Samaha","year":"1998","unstructured":"Samaha H, Dumontet C, Ketterer N, et al. Mantle cell lymphoma: a retrospective study of 121 cases.Leukemia. 1998;12:1281\u20131287.","journal-title":"Leukemia"},{"key":"BF02982552_CR8","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","volume":"89","author":"The Non-Hodgkin\u2019s Lymphoma Classification Project","year":"1997","unstructured":"The Non-Hodgkin\u2019s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma.Blood. 1997;89:3909\u20133918.","journal-title":"Blood"},{"key":"BF02982552_CR9","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","volume":"83","author":"ME Reff","year":"1994","unstructured":"Reff ME, Carner K, Chambers KS, at al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.Blood. 1994;83:435\u2013445.","journal-title":"Blood"},{"key":"BF02982552_CR10","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/j.1349-7006.1998.tb03280.x","volume":"89","author":"H Taji","year":"1998","unstructured":"Taji H, Kagami Y, Okada Y, et al. Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody.Jpn J Cancer Res. 1998;89:748\u2013756.","journal-title":"Jpn J Cancer Res."},{"key":"BF02982552_CR11","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","volume":"84","author":"DG Maloney","year":"1994","unstructured":"Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.Blood. 1994;84:2457\u20132466.","journal-title":"Blood"},{"key":"BF02982552_CR12","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low grade non-Hodgkin\u2019s lymphoma.Blood. 1997;90:2188\u20132195.","journal-title":"Blood"},{"key":"BF02982552_CR13","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","volume":"15","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin\u2019s lymphoma.J Clin Oncol. 1997;15:3266\u20133274.","journal-title":"J Clin Oncol."},{"key":"BF02982552_CR14","first-page":"1927","volume":"92","author":"B Coiffier","year":"1998","unstructured":"Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.Blood. 1998;92:1927\u20131932.","journal-title":"Blood"},{"key":"BF02982552_CR15","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.J Clin Oncol. 1998;16:2825\u20132833.","journal-title":"J Clin Oncol."},{"key":"BF02982552_CR16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1600-0609.1999.tb01725.x","volume":"62","author":"DT Nguyen","year":"1999","unstructured":"Nguyen DT, Amess JA, Doughty H, Hendry L, Diamond LW. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low- grade non-Hodgkin\u2019s lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients.Eur J Haematol. 1999;62:76\u201382.","journal-title":"Eur J Haematol."},{"key":"BF02982552_CR17","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1023\/A:1008265313133","volume":"9","author":"K Tobinai","year":"1998","unstructured":"Tobinai K, Kobayashi Y, Narabayashi M, et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group.Ann Oncol. 1998;9:527\u2013534.","journal-title":"Ann Oncol."},{"key":"BF02982552_CR18","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","volume":"18","author":"JM Foran","year":"2000","unstructured":"Foran JM, Rohatiner AZS, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.J Clin Oncol. 2000;18:317\u2013324.","journal-title":"J Clin Oncol."},{"key":"BF02982552_CR19","first-page":"4866","volume":"50","author":"JE Frodin","year":"1990","unstructured":"Frodin JE, Lefvert AK, Mellstedt H. Pharmacokinetics of the mouse monoclonal antibody 17-1A in cancer patients receiving various treatment schedules.Cancer Res. 1990;50:4866\u20134871.","journal-title":"Cancer Res."},{"key":"BF02982552_CR20","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1182\/blood.V69.2.584.584","volume":"69","author":"OW Press","year":"1987","unstructured":"Press OW, Appelbaum F, Ledbetter JA, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas.Blood. 1987;69:584\u2013591.","journal-title":"Blood"},{"key":"BF02982552_CR21","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.1996.14.7.1974","volume":"14","author":"MS Kaminski","year":"1996","unstructured":"Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.J Clin Oncol. 1996;14:1974\u20131981.","journal-title":"J Clin Oncol."},{"issue":"suppl 23","key":"BF02982552_CR22","first-page":"5929S","volume":"55","author":"JY Wong","year":"1995","unstructured":"Wong JY, Williams LE, Yamauchi DM, et al. Initial experience evaluating 90yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a phase I radioimmunotherapy trial.Cancer Res. 1995;55(suppl 23):5929S-5934S.","journal-title":"Cancer Res."}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02982552\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02982552.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02982552","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02982552.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T21:12:58Z","timestamp":1589058778000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02982552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,7]]}},"alternative-id":["BF02982552"],"URL":"https:\/\/doi.org\/10.1007\/bf02982552","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,7]]}}}